• 
• 
• 
• 
• 

• Services
  • Academic
  • Pharma/Biotech
  • Consumer Products
• Diagnostics
  • Diabetes
  • Prostate Cancer
  • Amyotrophic Lateral Sclerosis (ALS)
• About Us
  • Management Team
  • Board of Directors
  • Advisory Boards
  • Intellectual Property
  • Directions
• Tools And Resources
  • Publications
  • Metabolon in the News
  • Press Releases
  • Events
  • Webinars
  • Application Notes
  • Case Studies

Type 2 diabetes has a huge impact on patient quality of life and healthcare costs. According to the American Diabetes Association there are 20.8 million children and adults in the United States, or 7% of the population, who have diabetes. While an estimated 14.6 million have been diagnosed, unfortunately 6.2 million people (or nearly one-third) are unaware they have the disease. Managing the disease and its complications can last for 20 to 30 years. Long-term complications include cardiovascular disease, retinopathy, neuropathy, and nephropathy.

There is significant unmet medical need in diagnosing the diabetes progression, determining appropriate therapy, and predicting long-term outcomes.

Using our metabolomics-driven biomarker discovery platform , Metabolon has discovered a number of significant biochemical markers indicative of Type 2 diabetes. These markers are currently being incorporated as part of Metabolon’s Quantose™ Series of diagnostic products. The Quantose products will be targeted at different stages of diabetes: pre-diabetes, drug efficacy and complications of the disease.